MedTrace Logo

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

NCT02217930 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-10-29

No results posted yet for this study

Summary

The study designed to determine the effect induced by WCK 2349 on the QT interval.

The study will be conducted in two parts: 1) to determine the supratherapeutic dose; and 2) to assess the safety of high doses of single-dose administration of WCK 2349 on the QT interval.

Conditions

  • Qt Interval, Variation in

Interventions

DRUG

WCK 2349

DRUG

Placebo

DRUG

Moxifloxacin

Sponsors & Collaborators

  • Wockhardt

    lead INDUSTRY

Principal Investigators

  • Carlos Sanabria, MD · Spaulding Clinical Research Inc.

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2014-12-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02217930 on ClinicalTrials.gov